Science, Survival, and What Comes Next: Key Takeaways from the 2026 IASLC TTLC Meeting
IASLC TTLC 2026 spotlights patient voices, ctDNA MRD, EGFR co-mutations, and ADCs—plus real-world gaps in testing and multidisciplinary lung care.
The 2026 IASLC Targeted Therapies in Lung Cancer (TTLC) meeting proved to be one of the most energizing gatherings in recent memory for the lung cancer community. From deeply personal patient stories to cutting-edge science on targeted therapies, antibody-drug conjugates (ADCs), and circulating tumor DNA (ctDNA), the meeting offered both inspiration and a clear-eyed look at the work still ahead. Estelamari Rodriguez, MD, MPH, thoracic oncologist at the University of Miami Sylvester Comprehensive Cancer Center, shared her reflections on the highlights and hard questions that defined this year’s program.